...
【24h】

Use of antipsychotics in the management of schizophrenia during pregnancy.

机译:在妊娠期精神分裂症的治疗中使用抗精神病药。

获取原文
获取原文并翻译 | 示例
           

摘要

The rapid development of pharmacotherapy has resulted in a growing clinical importance for the treatment of the increasing number of women with schizophrenia during pregnancy. An evolving database on reproductive health safety factors for women with schizophrenia has begun to be of assistance in optimising clinical benefits for women with childbearing potential.Given the prevalence of antipsychotic use during pregnancy in women with schizophrenia, it is important for the clinician to have a prepared approach to the administration of these agents. In general, the use of psychotropic medication during pregnancy is indicated when risk to the fetus from exposure to this medication is outweighed by the risks of untreated psychiatric illness in the mother. The preponderance of evidence from registries to large health surveys indicate that treatment with antipsychotic medication confers either no or a small nonspecific risk for organ malformations.According to the relevant literature published on the safety of antipsychotic medication during pregnancy, the findings are encouraging; however, the currently available data are very limited. Until there are more controlled prospective data on the impact of drugs on fetal and later development, the clinician will continue to work in a state of potential uncertainty, weighing partially estimated risks against managing individual clinical problems. The aim for the clinician should be to provide the best information available regarding the scope of possible risks associated with the treatment of schizophrenia during pregnancy. On the basis of the available data, generalisation is impossible and recommendations should be made on a drug-by-drug basis. The risks and benefits must always be carefully weighed for each patient on an individual basis. Only a woman who is well enough to acknowledge her pregnancy and her mental illness can effectively weigh the relative and partially unknown risks of treatment with antipsychotic medication against the highly probable risks of illness exacerbation if untreated.
机译:药物疗法的快速发展已导致临床治疗越来越多的妊娠期精神分裂症妇女的临床重要性日益提高。不断发展的精神分裂症妇女生殖健康安全因素数据库已开始为优化具有生育能力的妇女的临床益处提供帮助。鉴于精神分裂症妇女怀孕期间使用抗精神病药的普遍性,对临床医生而言重要的是准备这些药剂的管理方法。通常,如果母亲未接受过精神病治疗的风险超过了胎儿因暴露于该药物而引起的风险,则表明在怀孕期间使用精神药物。从登记处到大型健康调查的大量证据表明,使用抗精神病药物治疗不会或不会给器官畸形带来很小的非特异性风险。但是,当前可用的数据非常有限。直到有更多关于药物对胎儿及以后发育的影响的前瞻性数据得到控制,临床医生将继续在潜在不确定性的状态下工作,权衡部分估计的风险与处理个别临床问题的权重。临床医生的目的应该是提供有关妊娠期间精神分裂症治疗可能的风险范围的最佳信息。根据现有数据,不可能一概而论,应根据药物逐一提出建议。必须始终仔细权衡每位患者的风险和收益。只有能够充分认识到自己的怀孕和精神疾病的妇女,才能有效权衡使用抗精神病药物治疗的相对和部分未知的风险与未经治疗的极有可能使疾病恶化的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号